The topical isoflavonoid NV-07alpha reduces solar-simulated UV-induced suppression of Mantoux reactions in humans.
UV radiation suppresses delayed-type hypersensitivity responses to intradermally injected tuberculin purified protein derivative in Mantoux-positive individuals. The effect of the topically administered isoflavonoid NV-07alpha, a synthetic derivative of the isoflavonoid equol, on UV-induced suppression of Mantoux reactions was assessed in 18 healthy Mantoux-positive volunteers. A single, fixed dose of solar-simulated UV radiation was delivered to the volunteers' lower backs. Different concentrations of NV-07alpha or its vehicle were applied to different sites within the irradiated field immediately after UV exposure and again 24 h later. Forty-eight hours after irradiation, Mantoux testing was performed at both the irradiated sites and adjacent, unirradiated sites. The intensity of Mantoux reactions was measured 72 h later with a reflectance erythema meter and by measuring the diameter of each reaction. Although lower concentrations of NV-07alpha (0.5 and 2 mM) did not prevent UV immunosuppression, 4 mM NV-07alpha partially but significantly attenuated UV-induced suppression of Mantoux-induced erythema. Minimal erythema doses were also determined for sites treated with NV-07alpha or its vehicle immediately after UV exposure. NV-07alpha had no significant effects on UV erythema. We conclude that 4 mM NV-07alpha prevented the suppressive effects of UV radiation on Mantoux responses in humans but did not affect UV-induced erythema at the concentrations used.
Friedmann
Adam C
AC
Dermatology, Melanoma and Skin Cancer Research Institute, Sydney Cancer Centre, University of Sydney at Royal Prince Alfred Hospital, New South Wales, Australia.
Halliday
Gary M
GM
Barnetson
Ross StC
RS
Reeve
Vivienne E
VE
Walker
Catherine
C
Patterson
Clare R S
CR
Damian
Diona L
DL
D000287:Administration, Topical; D000328:Adult; D004305:Dose-Response Relationship, Drug; D060754:Equol; D004890:Erythema; D005260:Female; D006801:Humans; D007529:Isoflavones / Q000008:administration & dosage* / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D012867:Skin / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology / Q000528:radiation effects*; D014466:Ultraviolet Rays
C007610:4',7-dihydroxy-3,4-dihydroisoflavone; D007529:Isoflavones; D060754:Equol